The responsiveness of A673 depends on MHC-I and partly ICAM-1, providing a rational to induce MHC-I and ICAM-1 expression to improve the efficacy of adoptive cellular therapies in pediatric sarcomas (Figure 9). This evidence concerns the gene ICAM1 and sarcoma.